safingol
Safingol is a lyso-sphingolipid protein kinase inhibitor. It has the molecular formula C18H39NO2 and is a colorless solid. Medicinally, safingol has demonstrated promising anticancer potential as a modulator of multi-drug resistance and as an inducer of necrosis. The administration of safingol alone has not been shown to exert a significant effect on tumor cell growth. However, preclinical and clinical studies have shown that combining safingol with conventional chemotherapy agents such as fenretinide, vinblastine, irinotecan and mitomycin C can dramatically potentiate their antitumor effects. In phase I clinical trials, it was found to be safe to co-administer with cisplatin, but caused reversible dose-dependent hepatotoxicity. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2004 (NCT00084812)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sphingosine kinase 1INHIBITOR
SPHK1 inhibitor
Chemistry & pharmacology
SMILES
CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO- Mol. weight
- 301.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSafingol ↗
- ChEMBLCHEMBL1442934 ↗
Also known as
- 2-aminooctadecane-1,3-diol
- dihydrosphingosine
- erythro-d-sphinganine
- safingol
- safingol
- safingol
- safingol
- safingol
- safingol hcl
- safingol hcl
- safingol hydrochloride
- safingol, (r-(r*,r*))-isomer
- safingol, ((r*,s*)-(+-))-isomer
- safingol, (s-(r*,s*))-isomer
- saginfol
- spc 100270
- spc-100270
- spc-100270
- spc-100270
- sphinganine
- threo-dihydrosphingosine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01553071 | Phase 1 | Nov 1, 2016 | South Plains Oncology Consortium |
| NCT00084812 | Phase 1 | Mar 1, 2004 | Cornell University, National Cancer Institute (NCI) |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| South Plains Oncology Consortium | Academic/Hospital | 1 | 1 | 1 | 2016 |